{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:47:30Z","timestamp":1790254050536,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12879-019-4047-7","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T15:04:04Z","timestamp":1558710244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical impact of tropism testing in a real-life cohort of HIV infected patients: a retrospective observational study"],"prefix":"10.1186","volume":"19","author":[{"given":"Laur\u00e8ne","family":"Deconinck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-5442","authenticated-orcid":false,"given":"Olivier","family":"Robineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Valette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Choisy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Bocket","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Meybeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Ajana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,24]]},"reference":[{"key":"4047_CR1","doi-asserted-by":"publisher","first-page":"e0132430","DOI":"10.1371\/journal.pone.0132430","volume":"10","author":"SFL van Lelyveld","year":"2015","unstructured":"van Lelyveld SFL, Drylewicz J, Krikke M, Veel EM, Otto SA, Richter C, et al. Maraviroc intensification of cART in patients with suboptimal immunological recovery: a 48-week, placebo-controlled randomized trial. PLoS One. 2015;10:e0132430.","journal-title":"PLoS One"},{"key":"4047_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrneurol.2015.248","volume":"12","author":"G Martin-Blondel","year":"2016","unstructured":"Martin-Blondel G, Brassat D, Bauer J, Lassmann H, Liblau RS. CCR5 blockade for neuroinflammatory diseases--beyond control of HIV. Nat Rev Neurol. 2016;12:95\u2013105.","journal-title":"Nat Rev Neurol"},{"key":"4047_CR3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3389\/fimmu.2015.00277","volume":"6","author":"E Van Der Ryst","year":"2015","unstructured":"Van Der Ryst E. Maraviroc - a CCR5 antagonist for the treatment of HIV-1 infection. Front Immunol. 2015;6:277.","journal-title":"Front Immunol"},{"key":"4047_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S1473-3099(10)70319-4","volume":"11","author":"LPR Vandekerckhove","year":"2011","unstructured":"Vandekerckhove LPR, Wensing AMJ, Kaiser R, Brun-V\u00e9zinet F, Clotet B, De Luca A, et al. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis. 2011;11:394\u2013407.","journal-title":"Lancet Infect Dis"},{"key":"4047_CR5","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Tests ph\u00e9notypiques et tests g\u00e9notypiques de d\u00e9termination du tropisme du VIH-1 et traitement par antagoniste du r\u00e9cepteur CCR5. 2009. http:\/\/www.has-sante.fr . Accessed 02 April 2018."},{"key":"4047_CR6","unstructured":"Prise en charge m\u00e9dicale des personnes vivant avec le VIH, recommandations du groupe d'experts. https:\/\/www.cns.sante.fr . Accessed 02 2018."},{"key":"4047_CR7","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1093\/jac\/dks539","volume":"68","author":"A Bonjoch","year":"2013","unstructured":"Bonjoch A, Pou C, P\u00e9rez-\u00c1lvarez N, Bellido R, Casadell\u00e0 M, Puig J, et al. Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial. J Antimicrob Chemother. 2013;68:1382\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"4047_CR8","first-page":"510.e1","volume":"21","author":"S Nozza","year":"2015","unstructured":"Nozza S, Galli L, Antinori A, Chiappetta S, Mazzotta F, Zaccarelli M, et al. Maraviroc 150 mg daily plus lopinavir\/ritonavir, a nucleoside\/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2015;21:510.e1\u20139.","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"4047_CR9","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1093\/jac\/dkw167","volume":"71","author":"L Bocket","year":"2016","unstructured":"Bocket L, Peytavin G, Alidjinou EK, Ajana F, Choisy P, L\u00ea M, et al. Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients. J Antimicrob Chemother. 2016;71:2651\u20133.","journal-title":"J Antimicrob Chemother"},{"key":"4047_CR10","first-page":"299","volume":"32","author":"P Pugliese","year":"2003","unstructured":"Pugliese P, Cuzin L, Enel P, Agher R, Alfandari S, Billaud E, et al. NADIS 2000, development of an electronic medical record for patients infected by HIV, HBV and HCV. Presse M\u00e9dicale Paris Fr 1983. 2003;32:299\u2013303.","journal-title":"Presse M\u00e9dicale Paris Fr 1983"},{"key":"4047_CR11","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jcv.2014.04.004","volume":"60","author":"P Ferrer","year":"2014","unstructured":"Ferrer P, Tello M, Montecinos L, Tordecilla R, Rodr\u00edguez C, Beltr\u00e1n C, et al. Prevalence of R5 and X4 HIV variants in antiretroviral treatment experienced patients with virologic failure. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2014;60:290\u20134.","journal-title":"J Clin Virol Off Publ Pan Am Soc Clin Virol"},{"key":"4047_CR12","first-page":"17","volume":"35","author":"V Svicher","year":"2012","unstructured":"Svicher V, Alteri C, Montano M, D\u2019Arrigo R, Andreoni M, Angarano G, et al. Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. New Microbiol. 2012;35:17\u201325.","journal-title":"New Microbiol"},{"key":"4047_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1089\/apc.2014.0212","volume":"29","author":"MW McCarthy","year":"2015","unstructured":"McCarthy MW, Genzen JR, Wilkin TJ, Singh HK. Use of a commercial HIV co-receptor tropism assay in clinical practice. AIDS Patient Care STDs. 2015;29:53\u20134.","journal-title":"AIDS Patient Care STDs"},{"key":"4047_CR14","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/0956462414546917","volume":"26","author":"H Wyatt","year":"2015","unstructured":"Wyatt H, Herman OM, Macartney M, Conibear T, Garcia-Diaz A, Booth C, et al. The utility of genotypic tropism testing in clinical practice. Int J STD AIDS. 2015;26:593\u20134.","journal-title":"Int J STD AIDS"},{"key":"4047_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.antiviral.2015.05.001","volume":"120","author":"JM Llibre","year":"2015","unstructured":"Llibre JM, Rivero A, Rojas JF, Garcia Del Toro M, Herrero C, Arroyo D, et al. Safety, efficacy and indications of prescription of maraviroc in clinical practice: factors associated with clinical outcomes. Antivir Res. 2015;120:79\u201384.","journal-title":"Antivir Res"},{"key":"4047_CR16","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/COH.0b013e328356e933","volume":"7","author":"C Boesecke","year":"2012","unstructured":"Boesecke C, Pett SL. Clinical studies with chemokine receptor-5 (CCR5)-inhibitors. Curr Opin HIV AIDS. 2012;7:456\u201362.","journal-title":"Curr Opin HIV AIDS"},{"key":"4047_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.medmal.2010.03.007","volume":"40","author":"I Poizot-Martin","year":"2010","unstructured":"Poizot-Martin I. CCR5-antagonists: contribution of a new antiretroviral class to the management of HIV infection. Med Mal Infect. 2010;40:245\u201355.","journal-title":"Med Mal Infect"},{"key":"4047_CR18","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1097\/QAD.0b013e328332d32d","volume":"23","author":"V Soriano","year":"2009","unstructured":"Soriano V, Perno C-F, Kaiser R, Calvez V, Gatell JM, di Perri G, et al. When and how to use maraviroc in HIV-infected patients. AIDS Lond Engl. 2009;23:2377\u201385.","journal-title":"AIDS Lond Engl"},{"key":"4047_CR19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1310\/hct1106-351","volume":"11","author":"TJ Wilkin","year":"2010","unstructured":"Wilkin TJ, Ribaudo HR, Tenorio AR, Gulick RM. The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients. HIV Clin Trials. 2010;11:351\u20138.","journal-title":"HIV Clin Trials"},{"key":"4047_CR20","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","volume":"359","author":"RM Gulick","year":"2008","unstructured":"Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429\u201341.","journal-title":"N Engl J Med"},{"key":"4047_CR21","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1468-1293.2011.00953.x","volume":"13","author":"M Pichenot","year":"2012","unstructured":"Pichenot M, Deuffic-Burban S, Cuzin L, Yazdanpanah Y. Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials. HIV Med. 2012;13:148\u201355.","journal-title":"HIV Med"},{"key":"4047_CR22","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1086\/630210","volume":"49","author":"Y Yazdanpanah","year":"2009","unstructured":"Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir\/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis Off Publ Infect Dis Soc Am. 2009;49:1441\u20139.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"4047_CR23","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/infdis\/jiu051","volume":"210","author":"A Castagna","year":"2014","unstructured":"Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210:354\u201362.","journal-title":"J Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4047-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4047-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4047-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T16:20:13Z","timestamp":1721319613000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4047-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,24]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4047"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4047-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,24]]},"assertion":[{"value":"14 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients have signed an agreement allowing the record of their data in a database (NADIS) approved by a French data protection authority (Commission nationale de l\u2019informatique et des libert\u00e9s (CNIL) 770134) []. As a retrospective survey and in accordance with the European General Data Protection Regulation (n<sup>o<\/sup> 2016\/679), this study has been locally registered in Dron Hospital. Furthermore, local ethical committee has approved this research (comit\u00e9 d\u2019\u00e9thique du Centre Hospitalier Gustave Dron).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"467"}}